Preclinical studies have probed the sensitivity of primary CD tumor cells (including USP8 mutant cells), EGFR expressing AtT20 mouse corticotroph tumor cells and ACTH-secreting pituitary adenomas in transgenic mice with corticotroph-specific human EGFR expression to EGFR inhibitors like gefitinib demonstrating that these inhibitors are a treatment option for USP8 mutated corticotropinas [11,54,55]. The gene discussed is USP8; the disease is neoplasm.